Roche and Entelos Announce Collaboration in Metabolic Disease Research
News May 25, 2006
Under the terms of the agreement, Roche will provide R&D funding and milestone payments, and Entelos will conduct biosimulation research using its Metabolism PhysioLab® platform, which utilizes a 'virtual patient' approach to predict the effects of a drug on metabolic pathways and/or biomarkers.
This approach will be useful to Roche in analyzing existing preclinical and clinical data in order to optimize future clinical trials.
"With the increase of diabetes and obesity on a global scale, Roche is dedicated to developing new therapies to treat chronic metabolic disorders," said Jacques Mizrahi, global head of metabolic and vascular diseases at Roche.
"As part of this commitment, we believe Entelos’ biosimulation capabilities and disease knowledge will complement Roche’s expertise in metabolic diseases and provide us with cutting edge technology that will enhance our drug discovery programs."
"Entelos is extremely pleased to be expanding our collaboration with Roche, a world leader in the adoption and deployment of systems biology solutions," stated James Karis, president and CEO of Entelos.
"With our capability to create virtual patients and simulate human biology, we believe that Entelos brings a deeper understanding of human biology to the R&D process."
Mouse Study Suggests That Dietary Fat, Not Carbs, Drives ObesityNews
A mouse study that made over 100,000 measurements of body weight and fat has concluded that the sole driver of obesity in mice is increased dietary fat content.READ MORE
Peering Inside ProteinsNews
The proteins in our bodies are sophisticated structures that perform specific jobs to keep us functioning and healthy. Understanding how a protein is wired could help researchers develop ways to control its activity. A new technique lets researchers look into the atomic structures of proteins to see that wiring.READ MORE